Matthew Kurian, Assistant Professor of Medicine at the University of Kentucky College of Medicine and Physician at St. Elizabeth Healthcare, shared a post on LinkedIn:
“Update in Triple Negative Breast Cancer.
Topline phase 3 results from BL-B01D1-307:
- Izalontamab brengitecan (iza-bren) – a bispecific EGFR × HER3 ADC.
- Improved PFS and OS vs physician’s choice chemotherapy in China.
- Patients had 1-2 prior lines of chemo and prior taxane exposure.
Meeting dual primary endpoints in metastatic TNBC is not trivial.
That said – important context:
- Comparator was physician’s choice chemo.
- 1-2 prior lines required.
- Not yet clear how many patients had prior ADC exposure.
- So we don’t yet know where this stacks up in modern sequencing.
Still, a phase 3 trial hitting both PFS and OS in this space deserves attention.
Full dataset pending presentation – but this adds meaningful momentum to the evolving metastatic TNBC landscape.”
Other articles about Breast Cancer on OncoDaily.